.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The quest for effective heart regeneration has faced significant challenges, particularly when translating pre-clinical laboratory success to aged human patients. Recent research on senotherapeutics in cardiac aging highlights that cellular senescence is a major barrier to successful therapy in patients older than 70 years. These dysfunctional cells create a hostile tissue microenvironment. Consequently, this environment prevents successful regeneration in the aging myocardium by inhibiting endogenous repair mechanisms.
The aged heart undergoes structural and functional changes driven by biological mechanisms like metabolic dysfunction and inflammaging. However, targeting senescent cells with senotherapeutics can effectively alleviate features like myocardial hypertrophy and fibrosis. Moreover, these drugs help clear the \"zombie cells\" that inhibit the heart's natural repair capacity. Consequently, these therapies rejuvenate the tissue microenvironment and activate endogenous regeneration. Therefore, they offer a promising adjunct to existing cardiac treatments.
Experimental medicine studies often rely on young animal models, which fail to reflect the reality of the actual patient population. Specifically, patients requiring regenerative treatments are usually elderly and possess a high senescent cell burden. Therefore, future myocardial therapies must undergo testing in pre-clinical models that strictly mimic the aged heart phenotype. Whether the approach is pharmacological, cell-based, or genetic, it requires a microenvironment conducive to repair. Furthermore, clinicians must prioritize models that accurately represent the biological complexity of aging patients to ensure clinical efficacy.
Senotherapeutics are pharmacological agents designed to target and either eliminate (senolytics) or modify (senomorphics) senescent cells to improve tissue function and health span.
Senescent cells secrete inflammatory factors known as the senescence-associated secretory phenotype (SASP). This creates a toxic environment that prevents cardiac stem cells and muscle tissue from repairing damage effectively.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research highlights senotherapeutics as a key adjunct to rejuvenate the aged heart and enhance the efficacy of cardiac regenerative therapies in elderly pat...
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
